Moreover, FG-3019 (pamrevlumab), a neutralizing antibody designed against CTGF, appears to be more potent than pirfenidone or nintedanib (PDGFR/VEGFR/FGFR inhibitor) in a mouse model of radiation-induced lung fibrosis [188]. The gene discussed is CCN2; the disease is pulmonary fibrosis.